A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Status:
Recruiting
Trial end date:
2022-11-14
Target enrollment:
Participant gender:
Summary
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and
rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle
cell lymphoma.